Mylan's Herceptin Advisory Committee May Be First Bumpy One For A Biosimilar
Executive Summary
US FDA did not address production problems in its briefing document for upcoming Oncologic Drugs Advisory Committee meeting, but manufacturing deficiencies found at Biocon's facility could prompt questions.